In the patients with lung cancer, diabetes mellitus
associates with increased survival compared with patients
without diabetes mellitus. Standard therapy should not be
withheld from patients with diabetes mellitus provided they
are otherwise fit: even if it may be considered a significant
comorbidity. The survival benefit may be of clinical importance
and should be focused on in future studies